BOSTON - A Massachusetts federal judge on March 26 largely denied a motion by Pfizer Inc. to dismiss a False Claims Act lawsuit alleging that the company promoted two drugs for off-label uses, allegedly while it was under a Corporate Integrity Agreement stemming from two earlier whistle-blower lawsuits alleging off-label promotion of one of the drugs (United States of America, et al., ex rel. Alex Booker, et al. v. Pfizer, Inc., No. 10-11166, D. Mass.; 2014 U.S. Dist. LEXIS 40102).